Abstract
Breakthrough infections in vaccinated individuals and reinfections among previously infected individuals are increasingly prevalent, especially during the Omicron wave. Here, we analyze data from SARS-CoV-2 surveillance across 35 California prisons to understand the impact of vaccination and prior infection on infectiousness of individuals with SARS-CoV-2 Omicron infections in prison settings. We estimate that vaccination, prior infection, and both vaccination and prior infection reduced an index case’s risk of transmitting to close contacts by 24% (9-37%), 21% (4-36%) and 41% (23-54%), respectively. Booster vaccine doses and more recent vaccination further reduced infectiousness. These findings suggest that although vaccinated and/or previously infected individuals remain infectious upon SARS-CoV-2 Omicron infection in this prison setting, their infectiousness is reduced compared to individuals without any history of vaccination or infection.
One Sentence Summary Vaccine-derived and naturally acquired immunity independently reduce the infectiousness of persons with Omicron SARS-CoV-2 infections.
Competing Interest Statement
JAL has received grants, honoraria, and speaker fees from Pfizer; grants and honoraria from Merck, Sharp, & Dohme; and honoraria from VaxCyte; all unrelated to the subject of this work. ATK and DS received funding from California Prison Health Care Receivership. The remaining authors have no disclosures.
Funding Statement
The study was funded by the University of California, San Francisco Department of Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of the University of California, San Francisco gave approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data requests may be made to California Correctional Health Care Services (CCHCS) and are subject to controlled access. All analytic code is publicly available.
